One of MassBioEd’s most popular courses, Biotech 101 for Non-Scientists is being offered THIS WEEK Sept. 18 – 19, and also this winter, December 4 – 5!
To register for FALL, click here.
To register for WINTER, click here.
**MassBio members get a $150 discount on registration**
Are you new to the life sciences industry? Do you need to have a better understanding of the science and technology driving the industry? Biotech 101 is a course designed specifically for the non-scientists. The program covers two full days of biotechnology information for non-science professionals who may be working on looking to work within a science-based industry.
Participants will benefit from several hands on activities using Lego DNA models, Agarose Gels, in addition to a DNA exercise featured here: http://youtu.be/JwRs2agM3Lk
1Globe Health Institute is a research institute located in Norwood, Massachusetts focusing on cancer and other disorders.
Cyta Therapeutics is a drug development company located in Winchester, Massachusetts.
Axios Biosciences is revolutionizing oncology drug discovery by identifying drugs active in the tumor microenvironment, an important component of tumor biology where tumors interact with non-malignant tissue and can dramatically affect drug sensitivity. Our ability to discover novel targets and active compounds, overlooked using traditional drug discovery approaches, can bridge the gap between preclinical research and clinical efficacy. Link
Synchroneuron is a clinical-stage, central nervous system focused company developing a new treatment for tardive dyskinesia (TD), an involuntary movement disorder that affects approximately one million patients in the United States with no approved treatment options. Synchroneuron has brought its lead drug candidate, SNC-102, from development to a Phase 2 study for TD in less than two years, and the company is exploring additional neurological indications affecting hundreds of thousands of patients who, like those with tardive dyskinesia, have limited or no available treatment options. Link
1) Genzyme eyes acquisitions as it doubles down on MS drug pipeline, Boston Business Journal, September 11, 2014
Genzyme says it is making a big bet on the field of multiple sclerosis and intends to use the full backing of its deep-pocketed parent, Sanofi, to develop new products and make acquisitions as needed. In an interview with Reuters, Genzyme’s Bill Sibold said the Cambridge-based developer of rare-disease fighting therapies has confidence in its existing lineup of MS drugs but is “very active” in seeking out new growth opportunities, namely smaller drug development companies and intellectual property that dovetail with Genzyme’s ongoing research. Link
2) Solid Ventures forges deal with Pfizer to test potential Duchenne drug, Boston Business Journal, September 9, 2014
A Cambridge biotech firm headed by a father with a quest to find a treatment for Duchenne muscular dystrophy is working with drug giant Pfizer to test one of its early-stage experimental drugs. “To take a risk on a small company like us speaks volumes about Pfizer’s commitment (to rare diseases),” company scientific analyst Joel Schneider said. Link
3) AbbVie and Biogen inch toward the FDA with once-a-month MS drug, Fierce Biotech, September 12, 2014
Partners Biogen Idec and AbbVie are touting late-stage results for their new, monthly multiple sclerosis treatment, preparing to hand in regulatory applications next year and contend in a crowded market. The drug, daclizumab, is a subcutaneous treatment designed to correct the immune system and improve symptoms of relapsing-remitting multiple sclerosis, the most common form of the disease. Link
4) UPDATE 2-U.S. FDA panel: Novo Nordisk’s liraglutide safe, effective for obesity, Reuters, September 11, 2014
Novo Nordisk’s drug liraglutide is safe and effective enough to warrant approval for use in chronically obese patients with at least one weight-related health issue, an advisory panel to the U.S. Food and Drug Administration concluded on Thursday. The panel voted 14 to 1 to recommend the drug, which is already approved to treat diabetes under the brand name Victoza. Link
5) Kitchen Vaccinations Spurred Harvard Alumnus to Make Record Gift, Bloomberg News, September 9, 2014
A nurse, Chan’s mother was a hygiene devotee who would wipe down restaurant utensils with ethanol-soaked cotton before letting her children eat with them, said Chan, 63, who yesterday announced a $350 million gift to the Harvard School of Public Health from his family’s Morningside Foundation. Link
Don’t miss the Fierce 15!
John Carroll, Editor-in-Chief of FierceBiotech, will be giving a live announcement of the Fierce 15 at BioPharm America again this year! The Fierce 15 is a hunt that involves the biggest ideas in biotech, the most daring characters in biopharma, and entrepreneurs doing things that haven’t been done before. The Fierce 15 will include drug developers or platform biotechs with the potential to have a huge impact on the treatment of human diseases. Be there when the news breaks!
Check out the keynote & opening plenary!
The Keynote Address will be given by Gary Nabel, Chief Scientific Officer at Sanofi, and will also join the Opening Plenary.
These are exciting times, because pharma companies are going back to their roots. There’s been a major shift toward external innovation and data-driven science that guides the development of new medicines. For academic research, we see more collaboration at earlier stages. For biotech, we see relationships built at different points in the evolution of new medicines, and we are using structures and support that incentivize both partners to achieve success,” said Nabel.
The Opening Plenary will address “Getting real: Biopharma innovation and its impact on patients” with:
- Barry Greene, President and COO at Alnylam Pharmaceuticals
- Adam M. Koppel, Senior VP and Chief Strategy Officer at Biogen Idec
- Richard Pops, Chairman and CEO at Alkermes plc.
- Karen Bernstein, Co-Founder, Chairman, and Editor-in-Chief at BioCentury (Moderator)
Global pharmaceutical companies already confirmed to send business development teams to BioPharm America include AstraZeneca; Bayer HealthCare; Bristol-Myers Squibb; EMD Serono; Merck; Novo Nordisk; Sanofi; and Shire.